"Neuromed - Istituto Neurologico Mediterraneo è un Istituto di Ricovero e Cura a Carattere Scientifico(I.R.C.C.S.) e un centro di rilevanza nazionale e di altissima specializzazione per patologie afferenti alla Neurochirurgia, Neurologia, Riabilitazione(cod.56,75-1 e 75-2) e Chirurgia Vascolare ed Endovascolare. È riconosciuto dal Ministero della Salute e dalla Regione Molise tra i centri che si distinguono per la qualità delle cure e la capacità di trasferire i risultati della ricerca e nellattività clinica quotidiana(ricerca traslazionale). Neuromed è convenzionato con il SSN e al cuore della sua missione cè una forte integrazione tra Cura, Ricerca e Didattica."

During the past decade, IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 1 clinical trials were completed, i.e. on average, 11.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla" are "Multiple Sclerosis" (3 trials), "Multiple Sclerosis, Relapsing-Remitting" (2 trials), "Relapsing Multiple Sclerosis" (2 trials), "Multiple Sclerosis, Primary Progressive" (1 trials) and "Primary Progressive Multiple Sclerosis" (1 trials). Many other conditions were trialed in "IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla" in a lesser frequency.

Most popular intervention types in "IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla" are "Drug" (8 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (7 trials), "Fenebrutinib" (2 trials), "Antihistamine" (1 trials), "Desloratadine given orally" (1 trials) and "Dexamethasone given orally" (1 trials). Other intervention names were less common.

The vast majority of trials in "IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla" are 9 trials for "All" genders.

Currently, there are NaN active trials in "IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".